OKYO Pharma Limited (OKYO)

OKYO Pharma Limited (OKYO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $77.1M; returns 1 day -4.8%, 1 week -0.7%, 1 year -37.5%.

OKYO Pharma Ltd is a clinical-stage biopharmaceutical company with no revenue from product sales, exclusively focused on the development of novel therapies for ocular diseases. The company's entire business model is centered on its lead and sole pipeline asset, urcosimod (formerly OK-101).

Groups OKYO belongs to

• Biotechnology
• Clinical Stage Biotech
• United Kingdom Companies
• Ophthalmology
• GPCR Targeting
• Healthcare
• Fast Track Designation
• Pain Management
• Biopharmaceutical

OKYO financial model: income statement, cash flow and balance sheet